Cancer Archives - Blogs & Articles

Evolution of Biopsies in Cancer Identification & Therapy

August 22, 2022August 11, 2023 MarketsandMarkets Conferences

Each year, various types of cancers account for over 10 million deaths worldwide meaning this ‘silent killer’ is quite possibly the most fatal disease known to mankind. Although a cure for cancer remains the ultimate goal of modern medicine, advancing technologies & equipment are allowing healthcare professionals to screen & detect possible signs of the illness much earlier in its lifecycle which leads to better disease management and allows a chain to reduce a patient’s eventual pain & suffering. While tissue biopsies remain the highest standard for identification of tumors…

Immuno-Oncology : The Latest Frontier in Cancer Therapy

April 28, 2022August 16, 2023 MarketsandMarkets Conferences

For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding our means to adequately cope, manage and possibly rebuff the disease which has so often reminded us of our mortality. Up until recently, Chemotherapy, Surgeries, Radiation & Targeted Drug therapies had been the go-to for…

BIOSIMILARS: Origins & The Path Forward

April 19, 2022August 16, 2023 MarketsandMarkets Conferences

Almost 7 years removed from the first FDA approved Biosimilar (Zarxio) in 2015, the US market for Biosimilars is projected to be highly beneficial over the next decade, for both pharmaceutical companies as well as patients, with RAND Corporation projecting estimated savings of over $54 Billion during this period. To truly comprehend such forecasts, a deeper understanding of what constitutes a ‘Biosimilar Drug’ is required. Essentially, the structure of a biosimilar is based on a pre-existing, approved drug known as a Biologic & possesses no significant clinical difference in safety,…

The technology and applications of single-cell analysis have advanced dramatically in the last five years- 2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference

July 30, 2021 MarketsandMarkets Conferences

2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference to be held on 9th – 10th November 2021 will host industry giants like San Diego Nanotechnology Infrastructure, CHDI Foundation, Brigham Young University, AbSci, Stowers Institute for Medical Research, University of Florence, Pfizer, l’Université et CHU de Montpellier and many more. The single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period. The growth in this market is driven by technological advancements in single-cell analysis products,…

Speaker Interview with Sebastien Tabruyn for the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

February 5, 2020 MarketsandMarkets Conferences

Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 10 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 30 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity In a recent interview with MarketsandMarkets, Mr. Sebastien Tabruyn shared his thoughts on the current challenges that…

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 26, 2019August 26, 2019 MarketsandMarkets Conferences

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1. This has made many tumors amenable to immunotherapy. However, the generalized nature of…

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 9, 2019August 9, 2019 MarketsandMarkets Conferences

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

July 31, 2019 MarketsandMarkets Conferences

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

July 15, 2019July 15, 2019 MarketsandMarkets Conferences

Washington D.C. [USA]: According to the Scientists, an autoimmune disease looks to be linked with testicular cancer that affects men. Known to us as ‘testicular cancer-associated paraneoplastic encephalitis’, it is the reason behind any serious neurological symptoms found in men. They lose control of the limbs, speech and eye movements progressively. The autoimmune disease starts with a testicular tumor, which seems to be the reason behind the immune system attacking the brain. Affected men find themselves undiagnosed or misdiagnosed often and relevant treatment is delayed. In a study that was published in…